Loomis, Sayles & Company
BCRX icon

Loomis, Sayles & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Loomis, Sayles & Company’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,356,216
Closed -$38.3M – 976
2022
Q1 		$38.3M Buy
2,356,216
+919,104
+64% +$14.7M 0.05% 178
2021
Q4 		$19.9M Buy
+1,437,112
New +$19M 0.02% 308

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company's BCRX Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 2,356,216 shares — an estimated $38.3M sold.

Loomis, Sayles & Company first reported a position in BCRX in Q4 2021 and held it in 2 quarters. The position peaked at $38.3M in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 2,356,216 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $38.3M.
  • Loomis, Sayles & Company first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Loomis, Sayles & Company's BioCryst Pharmaceuticals position peaked at $38.3M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.